Although the HK2 role as a biomarker in BC is still not clearly documented, Ciscato et al. [71] compiled, in a recent review, multiple studies reporting clinicopathological and/or prognostic associations in other malignancies, namely breast, prostate, gastrointestinal, lung, glioblastoma, ovarian, and cervical cancer. This evidence concerns the gene HK2 and cervical carcinoma.